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(foodborne) and occupational (inhalation) exposure and can cause nervous system damage. To model this, rats were
subacutely treated either with CdCl2 solution per os (3.0 mg kg
−1 b.w.) or nanoparticulate CdO2 (particle size ca 65 nm) by
intratracheal instillation (0.04 mg kg−1 b.w.) alone or in sequential combination. Nervous system effects were observed at
different levels of function (open field behavior, cortical electrical activity, nerve action potential) and some general
toxicological indicators were also measured. Three weeks of oral plus one week of intratracheal exposure caused significant
reduction of body weight gain and open field motility. Lengthening of latency of sensory evoked potentials, observed in all
treated rats, was also the most significant in the group receiving oral plus intratracheal treatment. Conduction velocity of the
tail nerve was likewise decreased in all treated groups. Several of the effects pointed to a potentiating interaction between
the two forms of Cd. Modeling environmental and occupational Cd exposure by oral and intratracheal application in rats was
feasible, with results suggesting serious negative health effects in humans suffering such a combined exposure. Copyright ©
2011 John Wiley & Sons, Ltd.
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47INTRODUCTION
Cadmium is a metal which is frequently encountered in
occupational and environmental settings, has no known
biological function in humans, and is toxic in small amounts. Its
presence in the environment (in air, soil, groundwater, etc.) is
partly due to human activity. The general population is exposed
mainly by contaminated drinking water or food: Cd levels in fruit,
vegetables and meat can reach 10 μg kg−1, in offal (kidney and
liver) they can reach 100–1000 μg kg−1 and in shellfish, 200–
2000 μg kg−1 (Galal‐Gorchev, 1991). Cultivated plants, first of all
cereals, tend to accumulate Cd from the soil. In areas surrounding
industrial plants with high Cd emission, house dust can also be a
noteworthy source of human exposure (Leroyer et al., 2001).
Cadmium is also present in tobacco smoke: each cigarette
contains about 2 μg of Cd, of which ca 50% is absorbed from the
inhaled smoke in the lungs (Elinder et al., 1983).
Cadmium also enters the body mainly via inhalation of metal
dust and fumes in occupational exposure. Cd was, and partly
still is, used steel and other alloys, in pigments, in nickel–
cadmium batteries and in electroplating. Measured airborne
levels were ca 30 μg m−3 (indoors in car body repair shops;
Vitayavirasuk et al., 2005) or 1–19 μg m−3 (outdoors, in bridge
maintenance; Conroy et al., 1995). Cadmium is absorbed from
the respiratory tract at 2–50%, depending on the particle size,
while gastrointestinal absorption is 5–20% (Chaney et al., 2004).
Absorbed Cd is transported via the blood to the main target
organs such as kidney, liver, bones and brain (Goering et al.,
1995).J. Appl. Toxicol. 2011; 31: 471–476 Copyright © 2011 JohnAcute inhalation of Cd‐containing fumes causes pulmonary
edema with respiratory symptoms (dyspnea, chest tightness,
metal fume fever). In a case reported by Okuda et al. (1997),
acute Cd poisoning with respiratory signs developed, in 3–
6 months, into a Parkinson‐like state (stiffness of the limbs,
bradykinesia, muscle rigidity) that did not improve with
antiparkinsonian medication. Amyotrophic lateral sclerosis, optic
nerve damage, striatal damage and peripheral polyneuropathy
were also observed as long‐term neurotoxic consequences of
Cd (Bar‐Sela et al., 2001; Fern et al., 1996; O’Callaghan and Miller,
1986; Viaene et al., 1999).
Natural phenomena (volcanic activity) and industrial high‐
temperature processes (smelting, casting, welding, cutting,
grinding, etc.) generate airborne metal‐containing particles,
including those in the submicron range (nanoparticles, NPs).
Beside the intensity of ventilation and the amount and
physicochemical properties of the inhaled particles, the adverse
effects in inhalational exposure depend largely on the particle
size (Oberdörster et al., 2000). Compared with microscopicWiley & Sons, Ltd.
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472particles, NPs have higher mobility within the organism,
including direct access to the CNS by penetrating tissue
boundaries like the alveolar and capillary wall, and the blood–
brain barrier (Elder et al., 2006; Kreyling et al., 2006).
In this work, the above‐mentioned general (foodborne) and
occupational (inhalational) exposure was modeled by giving Cd
to rats in two different chemical forms, and combining exposure
via the airways and the gastrointestinal tract. Our aim was to
study the adverse effects caused by Cd in different physico‐
chemical forms by behavioral and electrophysiological methods.
MATERIALS AND METHODS
Animals and Treatment
Young adult male Wistar rats (200 ± 20 g, 8 groups of 12 rats
each) were obtained from the university’s breeding center and
were housed in a GLP‐rated animal house (22 ± 1 °C, 30–60%
relative humidity, 12 h light/dark cycle with light on at 06:00),
and free access to tap water and standard rodent food.
Treatments were performed once daily, five times a week, and
lasted 3 or 4 weeks (see Table 1). The body weight of the
animals was measured before each treatment.
For oral application, CdCl2 (Reanal, Hungary; purity 99.5%)
was dissolved in distilled water to 1 ml kg−1 b.w. administration
volume and was given to the rats orally by gavage. The dose –
3.5 mg kg−1 b.w. – was based on earlier results by Papp et al.
(2003), where this dose caused slight changes in cortical
electrophysiological parameters (2× and 4× higher doses had
significant effects in that experiment, but the low dose was
chosen to avoid overdosing in the combinations).
For intratracheal application, NPs of CdO2 with 65.6 ± 12.4 nm
diameter were synthesized at the Department of Applied
Chemistry, University of Szeged. The NPs were suspended in
1% hydroxyethyl cellulose (HEC) dissolved in PBS (pH 7.4) to
have a physiologically neutral vehicle in which the NPs do not
aggregate rapidly. The intratracheal dose was equal to the lower
dose used in a previous experiment with CdO2 NPs (Papp and
Sárközi, 2008). The nanosuspension was instilled in the rats’
trachea under brief diethyl ether anesthesia (for details, see
Sárközi et al., 2009). The instilled volume was 1.0 ml kg−1 b.w.
Assuming a daily ventilation volume of ca 0.5 m3 kg−1 b.w. for
our rats, as suggested by the physiological data of Strohl et al.
(1997), the intratracheal dose applied was the same order of
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HEC, 1% hydroxyethyl cellulose dissolved in PBS. Group codes: Cd
Copyright © 2011 Johnwileyonlinelibrary.com/journal/jatthe Introduction (Vitayavirasuk et al., 2005; Conroy et al., 1995),
and the 70 and 550 μg m−3 used by Takenaka et al. (2004) in rat
inhalation exposure. However, direct comparison between
inhalation of NPs from the surrounding air and direct
introduction of NPs into the lower airways is not realistic
because of various uncertainties (e.g. exact data on absorption,
unknown particle size of industrial aerosols).Behavioural Investigation
The rats’ spontaneous locomotor behavior pattern was assessed
in an open field (OF) instrument 2 days after the last Cd
application. The OF box used was of 48 × 48× 40 cm size and
equipped with two arrays of infrared beam gates at floor level
and at 12 cm height (Conducta 1.0 System; Experimetria Ltd,
Budapest, Hungary). After 20–30 min of accommodation in the
test room, the animals were put into the center of the box one
by one for a 10 min session. Counts and time of the horizontal
(running), vertical (rearing) and local (grooming, etc.) activity as
well as horizontal run length were calculated from the beam
interruptions, where a more than 40 mm change in the location
of the rat during a time unit of 1 s was interpreted as running, a
smaller shift as local activity and no shift as immobility.
Electrophysiological Investigation
Electrophysiological recording was done on the day following
the OF test. Preparation for recording, and the recording itself,
were performed under urethane anesthesia (1000 mg kg−1 i.p.).
The left hemisphere was exposed, and spontaneous electrical
activity (electrocorticogram, ECoG) was recorded from the
primary somatosensory, visual and auditory areas for 6 min.
From this, the band spectrum according to the standard human
EEG bands (delta to gamma; Kandel and Schwartz, 1985) was
calculated. Then, evoked potentials (somatosensory, visual and
auditory) were recorded from the same sites by applying the
stimuli in trains of 50. Somatosensory stimulation was done by
square pulses (3–4 V; 0.05 ms; 1, 2 and 10 Hz frequency)
delivered through a pair of needles inserted into the contralat-
eral whiskery skin. Visual stimulation was performed by flashes
(1 Hz) of a high‐luminance white LED placed directly in front of
the contralateral eye of the rat. For acoustic stimulation, clicks
(1 Hz) were applied to the contralateral ear through the hollow
ear bar of the stereotaxic frame. Onset latency and duration of
the EPs were measured after averaging. From the tail nerve,ent time
reatments
al treatment Intratracheal treatment
After oral





3 weeks 1 week
, cadmium treated; V, vehicle treated.
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Nervous system effects of dissolved and nanoparticulate cadmiumcompound action potential was recorded by inserting a pair of
needle electrodes at the base of the tail for stimulation, and
another pair 50 mm distally for recording. Conduction velocity
was calculated from this distance and the onset latency of the
action potential. Relative refractory period was measured by
double stimuli with 1–10 ms inter‐stimulus interval, from the
extra delay of the second potential. The complete electrophys-
iological work was performed by means of the software
Neurosys 1.11 (Experimetria Ltd, Budapest, Hungary).
Finally, rats were sacrificed by an overdose of urethane,
dissected, and organ weights were measured. Relative organ
weights, on the basis of percentage body weight, were
calculated.
The study was approved by the Ethical Committee for the
Protection of Animals in Research of the University. During the
whole procedure, the principles (based on the EU‐conform
Hungarian law) of the Committee were strictly followed.Table 2. Relative organ weights (related to percentage
body weight); means ± SD, n= 12
Groups Brain Lungs Liver
V3 0.55 ± 0.04 0.36 ± 0.03 3.29 ± 0.33
Cd3 0.57 ± 0.03 0.37 ± 0.04 3.24 ± 0.15
V31 0.48 ± 0.04 0.44 ± 0.02 3.49 ± 0.25
Cd31 0.55 ± 0.05* 0.89 ± 0.15**†† 2.96 ± 0.15*†‡
V13 0.52 ± 0.03 0.49 ± 0.06 3.37 ± 0.14
Cd13 0.54 ± 0.04 0.73 ± 0.12** 3.40 ± 0.44
*,** P< 0.05, 0.01 vs own control; †,†† P< 0.05, 0.001 Cd31 vs
Cd3; ‡ P< 0.05 Cd31 vs Cd13.Statistical Evaluation
The distribution of data was checked for normality by means of
the Kolmogorov–Smirnov test. Data analysis was done by one‐
way ANOVA. Post hoc analysis of group differences was
performed by Fisher's least significant difference test, setting
the level of significance at P> 0.05.
RESULTS
Body and Organ Weights
As shown in Fig. 1, vehicle‐treated rats, including those with HEC
instillation, had approximately normal body weight gain.
Treatment with oral CdCl2 also had only minimal effect on the
body weight. Rats receiving CdO2 NPs into the trachea, however,
showed weight loss during the corresponding week.
Among the relative organ weights, those of the lung, brain
and liver showed significant changes (Table 2). The weight
increase of the lungs was significant vs the corresponding
control in both the group treated first with dissolved and then
with NP Cd (Cd31) and in the group receiving NP treatment firstFigure 1. Time course of the control ands treated rats’ body weight during
were measured at the end of the corresponding week (on Friday); week 0
coding (abscissa) see Table 1. *, **, ***P<0.05, 0.01, 0.001 vs the correspondi
Cd31 vs Cd13.
J. Appl. Toxicol. 2011; 31: 471–476 Copyright © 2011 John(Cd13), but not in the group receiving dissolved Cd only. The
treatment also caused an increase in the brain weight, which
was slight in Cd3 and Cd13 but obvious in Cd31. The relative liver
weight was significantly decreased in Cd31 vs own control and
also vs the other treated groups.Open Field Performance
Ambulation distance showed significant decrease in both
combination groups (Cd31 and Cd13) compared with their
corresponding controls (V31 and V13; Fig. 2A). Again, the effect
in Cd31 was significant also in comparison to the other treated
groups, and the same held true for the times spent in the four
basic forms of OF activity (Fig. 2B, C). The general trend was
decreased activity in all treated groups, and the change in Cd13
vs V13 was somewhat stronger than that in Cd3 vs V3 but
remained below significance.Electrophysiological Effects
There were no noteworthy changes in the spontaneous cortical
activity. In the somatosensory EPs, significant latency increase at
every stimulation frequency (1, 2 and 10 Hz) vs thethe weeks of treatment (see insert). Mean ± SD, n=12; the values plotted
data are those from the Friday preceding the first treatment. For group
ng control; #, ###P<0.05, 0.001 Cd31 or Cd13 vs Cd3; &&, &&&P<0.01, 0.001
Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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Figure 2. Open field activity of the control and treated rats at the end
of treatment. (A) Ambulation distance; (B) time spent in ambulation and
rearing; (C) time spent in local activity and immobility. Mean ± SD,
n=12. Groups are marked on the abscissa. Significance marking as in
Fig. 1.
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474corresponding control was seen only in the Cd31 combination
group (Fig. 3A). The frequency‐dependent extra lengthening of
latency was, on the contrary, more pronounced both in Cd3 and
in Cd31 than in the controls. Duration of the somatosensory EP
showed a similar trend to that seen with the latency but this
remained below significance (not shown).
The visual and auditory EPs were also significantly length-
ened by Cd application in the groups Cd3 and Cd31, but not in
Cd13 (Fig. 3B). Decreased conduction velocity of the tail nerve
was found in all treated groups (Fig. 4A), but here there was
no difference between various treatments, unlike what was
seen in the cortical evoked responses. The trend of lengthen-
ing of the relative refractory period (not shown) indicated the
increased fatigability of the nerve in the treated rats (as did
the frequency‐dependent latency lengthening of the somato-
sensory EP).
DISCUSSION
The electrophysiological effects of Cd seen in the present work
were similar to those obtained in earlier experiments withCopyright © 2011 Johnwileyonlinelibrary.com/journal/jat4–12‐week oral Cd exposure (Papp et al., 2003) and with intra-
tracheal application of nanoparticulate Cd (Papp and Sárközi,
2008), which indicated that the applied Cd most probably
reached the central and peripheral nervous system and was
responsible for the changes. Absorption of Cd following
inhalation has been described repeatedly. Takenaka et al.
(2004) found Cd in the blood, liver and kidney of rats after
inhalation of 40 nm Cd oxide particles. In exposed workers,
elevated urine Cd level was associated with reduced visuomotor
performance and difficulties with concentration and stance
(Viaene et al., 2000). Cases of degenerative CNS disease were
also explained by the effect of Cd (Bar‐Sela et al., 2001).
The toxic effects of Cd, observed in the present work, were
mostly stronger in the combination groups (Cd13 and Cd31)
than in the group treated with dissolved Cd only (Cd3); and
were the strongest in Cd31 where the rats received 3 weeks
oral then 1 week intratracheal exposure. The amount of Cd
instilled was much less than that given previously per os (see
Table 1), indicating a potentiating, not merely additive, effect.
It can be supposed that, if during the 3 weeks of oral Cd
treatment the blood–brain barrier was weakened (as described
by Shukla et al., 1996), the Cd‐containing NPs applied
afterwards had higher chance of penetrating it and entering
the brain. This seems to apply for the frequency‐dependent
lengthening of the somatosensory evoked potential and for
the OF motility. A potentiation‐like effect was also seen in the
time course of the body weight, and in the relative brain and
liver weight. In the above‐mentioned experiment of Papp and
Sárközi (2008), 6 weeks of intratracheal application of a 10‐fold
dose (0.4 mg kg−1) of similar CdO2 NPs was needed to achieve
significant CNS effects, which is another argument for the
potentiating interaction.
Within the nervous system, Cd is known to affect a number of
functions. Cd2+ ions block voltage‐gated Ca channels, resulting
in disturbed stimulus‐dependent transmitter release and slowed
conduction (Suszkiw et al., 1984), which is in line with reduced
nerve conduction velocity and lengthened cortical response
latency observed in our treated rats. Cd also decreases astrocytic
glutamate uptake (Liu et al., 2008), which may lead to
desensitization of postsynaptic receptors in afferent pathways
and to suppressed cortical responses.
Open field hypomotility (reduced ambulation distance), seen
first of all in the rats receiving combined treatment, was
probably a consequence of disturbances to the dopaminergic
system, another effect of Cd described in experimental work
(Rajanna et al., 1990; Flora and Tandon, 1987), and in children
with environmental exposure (de Burbure et al., 2006). Beyond
the above‐mentioned general effect of Cd on synaptic function,
oxidative stress caused by Cd (Kumar et al., 1996) may
specifically affect dopaminergic neurons (Alexi et al., 2000)
and the effect of the metal on tyrosine hydroxylase (Deskin et
al., 1981) may also be involved. Cd administration for several
weeks was found to alter also brain acetylcholinesterase activity
(Carageorgiou et al., 2004; Pari and Murugavel, 2007) which may
affect both spontaneous and evoked cortical activity via the
ascending reticular cholinergic activation.
The results showed that the described model of environ-
mental and occupational Cd exposure based on oral and
intratracheal application in rats was feasible. Its implementa-
tion indicated that such a combined exposure may have
serious negative health effects in humans and hence requires
further investigation.J. Appl. Toxicol. 2011; 31: 471–476Wiley & Sons, Ltd.
Figure 3. Onset latency of the cortical evoked potentials. (A) Somatosensory response obtained with 1, 2 and 10 Hz stimulation (see insert); (B) visual
and auditory (VIS and AUD, see insert) response. Mean ± SD, n=12. Groups are marked on the abscissa. *, **, ***P<0.05, 0.01, 0.001 vs the
corresponding control at identical stimulation rate; #P<0.05 Cd31 vs Cd3 at identical stimulation rate; º, ºº, ºººP<0.05, 0.021, 0.001 value obtained at 2 or
10 Hz vs that at 1 Hz within the same group.
Figure 4. Conduction velocity of the tail nerve. Groups are marked
on the abscissa. Mean ± SD, n=12. **, ***P<0.01, 0.001 vs the
corresponding control.
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